2nd Oncology Beyond the Obvious (OBTO) In-Person Conference | Lung Cancer [Video]

Papers
a) Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC (FLAURA-2) from NEJM, 2023
b) MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Conference Directors: Dr. Amish Vora & Dr. Ullas Batra
Organizing Chairperson: Dr. Purvish Parikh
Scientific Co-chairpersons: Dr. Senthil Rajappa & Dr. Tarini Prasad Sahoo

Chairperson – Dr. Harit Chaturvedi
Moderator – Dr. Ullas Batra
Expert – Dr. Shailesh Bondarde